Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Zolgensma
Zolgensma
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Novartis
SMA
Zolgensma
gene therapy
Flag link:
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
BioPharma Dive
Novartis
gene therapy
Zolgensma
SMA
Europe
Flag link:
Novartis cuts 275 jobs at Illinois site to consolidate Zolgensma manufacturing in North Carolina
Novartis cuts 275 jobs at Illinois site to consolidate Zolgensma manufacturing in North Carolina
Endpoints
Novartis
layoffs
gene therapy
Zolgensma
drug manufacturing
Flag link:
Novartis sales of Zolgensma gene therapy slow as market shifts
Novartis sales of Zolgensma gene therapy slow as market shifts
BioPharma Dive
Novartis
gene therapy
spinal muscular atrophy
SMA
Zolgensma
Flag link:
Gene therapy is saving lives, but key challenges to realize its full potential
Gene therapy is saving lives, but key challenges to realize its full potential
MedCity News
gene therapy
Novartis
Zolgensma
Roctavian
Zynteglo
Skysona
Flag link:
Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper
Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper
BioSpace
Novartis
Zolgensma
data manipulation
SMA
Flag link:
Novartis reports deaths of two patients treated with Zolgensma gene therapy
Novartis reports deaths of two patients treated with Zolgensma gene therapy
BioPharma Dive
Novartis
gene therapy
Zolgensma
SMA
patient deaths
spinal muscular atrophy
Flag link:
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Motley Fool
Novartis
M&A
AveXis
Zolgensma
Endocyte
Pluvicto
The Medicines Company
Levqio
Flag link:
Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy
Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy
Fierce Biotech
AviadoBio
demential
Zolgensma
AVB-101
gene therapy
Flag link:
Novartis manufacturing facility in North Carolina gets FDA all-clear to produce, ship gene therapies
Novartis manufacturing facility in North Carolina gets FDA all-clear to produce, ship gene therapies
Endpoints
Novartis
gene therapy
North Carolina
FDA
Zolgensma
Flag link:
New Data Reinforces Impact of Novartis' Gene Therapy on SMA
New Data Reinforces Impact of Novartis' Gene Therapy on SMA
BioSpace
Novartis
gene therapy
spinal muscular atrophy
Zolgensma
Flag link:
Novartis dumps Rett gene therapy caught up in Zolgensma scandal in cull of pipeline prospects
Novartis dumps Rett gene therapy caught up in Zolgensma scandal in cull of pipeline prospects
Fierce Biotech
Novartis
Rett Syndrome
AVXS-201
Zolgensma
gene therapy
Flag link:
Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?
Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?
Fierce Pharma
Novartis
Europe
Zolgensma
SMA
spinal muscular atrophy
Flag link:
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Endpoints
Regenxbio
gene therapy
patents
Novartis
Zolgensma
SMA
Flag link:
Novartis to launch new Zolgensma trial after FDA lifts restriction
Novartis to launch new Zolgensma trial after FDA lifts restriction
Reuters
Novartis
Zolgensma
clinical trials
SMA
FDA
Flag link:
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up
Fierce Pharma
Novartis
SMA
spinal muscular atrophy
Zolgensma
Roche
Evresdi
Flag link:
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
Xtalks
Novartis
Zolgensma
SMA
gene therapy
Flag link:
Zolgensma flatlines, but Spinraza isn’t the beneficiary
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Flag link:
Pages
1
2
3
4
5
next ›
last »